These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Raffetto JD; Khalil RA Biochem Pharmacol; 2008 Jan; 75(2):346-59. PubMed ID: 17678629 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Kadoglou NP; Liapis CD Curr Med Res Opin; 2004 Apr; 20(4):419-32. PubMed ID: 15119978 [TBL] [Abstract][Full Text] [Related]
7. [The role of matrix metalloproteinases in the development of vascular complications of diabetes mellitus--clinical implications]. Rogowicz A; Zozulińska D; Wierusz-Wysocka B Pol Arch Med Wewn; 2007 Mar; 117(3):43-8. PubMed ID: 17718052 [TBL] [Abstract][Full Text] [Related]
8. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases. Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693 [TBL] [Abstract][Full Text] [Related]
9. Role of metalloproteinases and tissue inhibitors of metalloproteinases during cardiopulmonary bypass in rats. Guenzinger R; Lahm H; Wottke M; Lange R ASAIO J; 2012; 58(3):204-11. PubMed ID: 22395114 [TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Thrailkill KM; Clay Bunn R; Fowlkes JL Endocrine; 2009 Feb; 35(1):1-10. PubMed ID: 18972226 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in hamster aortic atherosclerosis: correlation with in-situ zymography. Faia KL; Davis WP; Marone AJ; Foxall TL Atherosclerosis; 2002 Feb; 160(2):325-37. PubMed ID: 11849655 [TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease. De S; Fenton JE; Jones AS J Laryngol Otol; 2005 Jun; 119(6):436-42. PubMed ID: 15992468 [TBL] [Abstract][Full Text] [Related]
15. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. Goncalves I; Bengtsson E; Colhoun HM; Shore AC; Palombo C; Natali A; Edsfeldt A; Dunér P; Fredrikson GN; Björkbacka H; Östling G; Aizawa K; Casanova F; Persson M; Gooding K; Strain D; Khan F; Looker HC; Adams F; Belch J; Pinnoli S; Venturi E; Kozakova M; Gan LM; Schnecke V; Nilsson J; Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1723-31. PubMed ID: 25953645 [TBL] [Abstract][Full Text] [Related]
16. Matrix Metalloproteases in Arterial Hypertension and their Trend after Antihypertensive Treatment. Hopps E; Lo Presti R; Caimi G Kidney Blood Press Res; 2017; 42(2):347-357. PubMed ID: 28618427 [TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease. Verstappen J; Von den Hoff JW J Dent Res; 2006 Dec; 85(12):1074-84. PubMed ID: 17122157 [TBL] [Abstract][Full Text] [Related]
19. The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study. Mroczko B; Groblewska M; Barcikowska M J Alzheimers Dis; 2013; 37(2):273-83. PubMed ID: 23792694 [TBL] [Abstract][Full Text] [Related]
20. An alternate perspective on the roles of TIMPs and MMPs in pathology. Moore CS; Crocker SJ Am J Pathol; 2012 Jan; 180(1):12-6. PubMed ID: 22033229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]